linjc16/ctgov huggingface dataset:
Effect Of Rilapladib (SB-659032) On Platelet Aggregation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the effects of repeat doses of SB-659032 with placebo on platelet aggregation in subjects.

Official Title
-----------------
A Double Blind, Placebo Controlled, Parallel Study to Evaluate Effects of Repeat Doses of Rilapladib on Platelet Aggregation in Healthy Male Volunteers

Conditions
-----------------
Healthy Subjects, Atherosclerosis

Intervention / Treatment
-----------------
* Drug: Rilapladib (SB-659032)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects with QTc < 450 msec as measured at screening. Exclusion Criteria: History of asthma. Smokers.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Rilapladib (SB-659032)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collagen EC50 values on Day 35 (or 21 days post last dose) as determine by optical aggregometry. |  | on Day 35 (or 21 days post last dose) as determine by optical aggregometry | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collagen EC50 values on Day 1 and Day 14 as determined by optical aggregometry Plasma Lp-PLA2 activity Clinical safety data Concentrations of rilapladib and SB-664601. |  | on Day 1 and Day 14 as determined by optical aggregometry | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
platelet aggregation, SB-659032, rilapladib
New York City (NYC) Health eHearts Pay for Quality Pilot

Study Overview
=================
Brief Summary
-----------------
Do monetary incentives in small independent primary care practices improve the delivery of preventive services as recommended by U.S. Preventive Services Task Force (USPSTF) guidelines for cardiovascular health?

Detailed Description
-----------------
The NYC DOHMH received a private donation from the Robin Hood Foundation to provide monetary incentives to small practices for improving their delivery of preventive services in neighborhoods experiencing health disparities. Practices recruited by NYC DOHMH to adopt an electronic health record will be randomized to receive monetary incentives for improving both patient outcomes and delivery of care on: aspirin therapy, blood pressure control, cholesterol control, and smoking cessation intervention. The set of quality measures are referred to the ABCS. The NYC DOHMH will be collecting provider surveys on their experience on quality measurement and participation in other pay-for-performance programs, as well as transmit aggregated information on their performance on the ABCS to DOHMH on a monthly basis.

Official Title
-----------------
Program Evaluation of New York City Health eHearts Pay for Quality Program

Conditions
-----------------
Hypertension, Diabetes, Smoking, Ischemic Cardiovascular Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary Care Providers Exclusion Criteria: Specialists Pediatricians Obstetricians Gynecologists

Ages Eligible for Study
-----------------
Minimum Age: 22 Years

Sexes Eligible for Study
-----------------
Male

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Quality Payment and all clinical reminders turned on | |
| 2<br>Quality Payment and ABCS measures reminders turned on | |
| 3<br>Quality Payment and non-ABCS measures reminders turned on | |
| 4<br>Quality Reporting and Recognition with all clinical reminders turned on | |
| 5<br>Quality Reporting and Recognition with ABCS measures reminders turned on | |
| 6<br>Quality Reporting and Recognition with non-ABCS measures reminders turned on | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| percent of patients eligible for quality measures (ABCS) |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| use of EHR clinical reminders |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pay for Quality, Provider, Clinical Decision Support, Quality Reporting, Quality Measurement
Single-Cell Transcriptomics of the Peritoneal Microenvironment of Colorectal PC

Study Overview
=================
Brief Summary
-----------------
Single cell transcriptomics of CRC PC samples

Detailed Description
-----------------
Research methodology Before inclusion of patients, patients will be screened for the presence of hepatitis B, hepatitis C and HIV to ensure researcher safety. During cytoreductive surgery, a total of five samples of tumoral tissue will be acquired. Three of those samples will be utilized for ScRNASeq analysis, and two samples of a macrometastasis will be snap frozen and cryopreserved. Single-cell RNA-Sequencing analysis We will comprehensively catalog the stromal cell types in the microenvironment of colorectal cancer peritoneal metastases utilizing single-cell RNA sequencing (scRNAseq) on three samples (one of which should preferably originate from the omentum majus, to encompass milky spots) acquired from surgical waste material of patients undergoing cytoreductive surgery. After sample prelevation, samples will be transported as soon as possible while cooled and submerged in 10% PBS to the VIB facilities, where single cell suspensions will be made according to standard protocols. After cell selection by FACS (CD45+ and live/dead stain, to ensure a 50/50 mix of immune and stromal cells) and library prep, ScRNASeq will be performed. Single cell sequencing analysis will allow us to identify cell clusters that by usage of marker genes will be assigned to different known cell lineages. After annotation of data, a landscape of the composition of the tumor stroma will be acquired.

Official Title
-----------------
The Role of the Peritoneal Microenvironment in the Pathogenesis of Colorectal Peritoneal Carcinomatosis: Single-cell Transcriptomics

Conditions
-----------------
Peritoneal Metastases

Intervention / Treatment
-----------------
* Procedure: CRC+HIPEC


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing CRS+HIPEC for PC of colorectal origin Exclusion Criteria: Previous HIPEC/PIPAC
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: CRC+HIPEC|Sample prelevation of cytoreductive surgery|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Single-cell transcriptomics | A transcriptional single-cell RNA seq atlas of gene expression data will be reported | 24 months |
Metacognition Assessment in Patient With Multiple Sclerosis

Study Overview
=================
Brief Summary
-----------------
This study will assessed the level of consciousness of MS patients suffering of cognitive and motor disorders. Understanding the awareness of the disease is crucial to allow better management of these patients. It has been shown, for other neurological pathologies, that a lack of awareness of deficits leads to inefficient rehabilitation and a disorder of understanding the impact of deficits in daily activities. Metacognition could be altered with age, so we will include participants between 18 and 60 years old.

Detailed Description
-----------------
Subject who have to do neurological assessement by the Multiple sclerosis Functional Composite (MSFC) will be enrolled. The patient will estimate the time to undergo the test. This time will be compared to the time really make by the patient to realise test.

Official Title
-----------------
Metacognition Assessment in Patient With Multiple Sclerosis

Conditions
-----------------
Multiple Sclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of multiple sclerosis Voluntary for participate to study Exclusion Criteria: Neurological disease other than Multiple Sclerosis psychiatric disease, other than depressiveness illicit substance abuse Persons referred to in Articles L1121-5 to 8 of the French Public Health Code

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Metacognitive precision | Metacognitive precision based on Multiple Sclerosis Functional Composite (MSFC) score | Day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Multiple Sclerosis, Multiple Sclerosis Functional Composite (MSFC), Metacognition
Clinical Outcome of Laparoscopic or Robotic Metroplasty for Uterine Isthmocele

Study Overview
=================
Brief Summary
-----------------
To evaluate the clinical outcomes of conventional or robotic - laparoscopic metroplasty for uterine isthmocele with the aid of a bending probe.

Official Title
-----------------
Clinical Outcome of Laparoscopic or Robotic Metroplasty for Uterine Isthmocele

Conditions
-----------------
Laparoscopic or Robotic Metroplasty

Intervention / Treatment
-----------------
* Procedure: C/S


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: > 20 years of women uterine isthmocele status post laparoscopic or robotic metroplasty with a bent uterine sound Exclusion Criteria: Those underwent traditional open surgery.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: C/S|laparoscopic or robotic metroplasty|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of prolonged menstrual bleeding condition | Symptoms improvement and perioperative complications | 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of scar defect size | Symptoms improvement and perioperative complications | 10 years |
Why in Hospital - Factors Determining Time to Discharge Readiness After Arthroplasty Surgery

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate patient related factors determining length of stay in hospital after arthroplasty surgery.

Detailed Description
-----------------
To evaluate why the patient is in hospital after surgery, when predefined discharge criteria are met, which patient related clinical problems hinder fulfilling of the discharge criteria, and to evaluate actual length of stay in hospital. All consecutive patients scheduled for total hip or knee arthroplasty are included in the trial.

Official Title
-----------------
Why in Hospital - Factors Determining Time to Discharge Readiness After Arthroplasty Surgery: An Prospective Observational Study

Conditions
-----------------
Pain, Nausea, Vomiting, Dizzyness, Fatigue, Organizational Concerns, Ect.

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients scheduled for total hip or knee arthroplasty Exclusion Criteria: Age under 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with Osteoarthrosis<br>All consecutive patients scheduled for total hip or knee arthroplasty | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient related factors determining length of stay in hospital |  | Daily (average 2 days) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of stay in hospital |  | At discharge (average 2 days) | 
| Time till fulfilling of predefined discharge criteria |  | At discharge (average 2 days) |
Dezoxide Suppresses Sufentanil-induced Cough

Study Overview
=================
Brief Summary
-----------------
Dizocine (0.03 mg/kg) or saline followed by sufentanil 0.4ug/kg was administered, and induction was completed with 3 min of observation. Heart rate and mean arterial pressure (MAP) were recorded before induction of anesthesia, before and 1 min after intubation, and side effects during induction, such as vomiting, hypoxemia (SpO2 <90%), or other expected effects. The number of coughs was recorded in both groups, and the severity of cough was defined as follows: mild, 1-2 coughs; moderate, 3-4 coughs; severe, 5 or more coughs.

Official Title
-----------------
Low-dose Dezoxide Suppresses Sufentanil-induced Cough During Induction of General Anesthesia in Patients Undergoing Cardiac Surgery: a Prospective, Randomized, Controlled Trial

Conditions
-----------------
Sufentanil-induced Cough

Intervention / Treatment
-----------------
* Drug: Intravenous dizocine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients admitted for elective valve surgery, artificial vessel replacement or coronary artery bypass graft surgery; Age 18 80 years old; Sex is not limited; ASA class II III; NYHA Class II-III; Patients or their family members have signed the clinical trial informed consent form Exclusion Criteria: Upper respiratory tract infection within the last two weeks; Long history of smoking; chronic obstructive pulmonary disease; Highly reactive airway diseases such as bronchitis and asthma; Presence of high cranial pressure, high eye pressure, pulmonary alveolus; Malignant tumor, hematological disease, severe liver and kidney dysfunction, recent serious infection, etc.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: control<br> | |
| Experimental: Dezocine<br>intravenous dezocine (0.03mg/kg diluted to 5 ml) | Drug: Intravenous dizocine<br>* Intravenous dizocine (0.03mg/kg diluted to 5 ml)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sufentanil-induced cough | rate and severity of cough after sufentanil injection | 2 minutes after intubation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| heart rate | heart rate during induction of general anesthesia | 2 minutes after intubation | 
| mean arterial pressure | mean arterial pressure during induction of general anesthesia | 2 minutes after intubation | 
| SpO2 | SpO2 during induction of general anesthesia | 2 minutes after intubation |
A New and Innovative Method for CO2 Removal in Anesthetic Circuits: Replacing Chemical Granulate

Study Overview
=================
Brief Summary
-----------------
The drawbacks of chemical CO2 absorbers include the production of compounds harmful to patients that also lead into increased cost and environmental impact, as well as the daily disposal of compound special waste. Sustainable management of general anesthesia is a growing concern. Continually diluting anesthetic circuits, and the disposal of chemical granulate are serious environmental problems.

Detailed Description
-----------------
DMF Medical has developed a next-generation CO2 filter in order to address the safety issues with current chemical CO2 absorbers in anesthesia. memsorb uses patented advanced medical membrane technology to filter CO2 from anesthetic circuits rather than absorbing via a chemical reaction. This game changing technology relies on a polymeric membrane core (similar to the ones used in oxygenators for cardiac surgery) that selectively allows CO2 to leave the rebreathing system, while maintaining the anesthetic vapor in the circuit. memsorb is a cartridge similar in size and shape to current solutions that simply clicks in place.

Official Title
-----------------
A New and Innovative Method for CO2 Removal in Anesthetic Circuits:

Conditions
-----------------
Anesthesia

Intervention / Treatment
-----------------
* Device: memsorb


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American Society of Anesthesiologists Physical Status Class I, II, III (low-medium risk patient) English-speaking patients Exclusion Criteria: Self-reported as pregnant American Society of Anesthesiologists Physical Status Class IV (high risk patient) Patients scheduled for emergency surgery Documented respiratory disease, including COPD and severe asthma Documented elevated pressure in the brain (intra cranial pressure, ICP)
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control<br>Patients receive standard care with a standard CO2 absorber and agree to include their data in the study. | |
| Experimental: memsorb<br>Patients agree to receive standard care but using memsorb, the new CO2 filter evaluated in this study. | Device: memsorb<br>* memsorb is a CO2 filter replacing current chemical CO2 absorbers<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| End Tidal CO2 | Concentration of carbon dioxide during expiratory cycle. | Up to 12h | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
co2 removal, anesthesia
The Effect of Laparoscopic Surgery on Ovarian Reserve According to Cyst Types

Study Overview
=================
Brief Summary
-----------------
The aim of our study is to compare the effect of laparoscopic ovarian cystectomy on ovarian reserve in terms of different cyst types.

Detailed Description
-----------------
Participants who will be treated surgically for ovarian cysts will be included in the study. Anti-Mullerian Hormone (AMH) levels of the participants will be investigated before the surgery and 6 months after the surgery. All surgeries will be performed under general anesthesia laparoscopically. After histopathological evaluation, the participants will be divided into three groups; Group 1: Endometrioma, Group 2: Mature cystic teratoma (Dermoid cyst) and Group 3: Serous or mucinous cystadenoma. A total of fifty-five women will be included in the study.

Official Title
-----------------
The Effect of Laparoscopic Surgery on Ovarian Reserve According to Cyst Types

Conditions
-----------------
Ovarian Cysts

Intervention / Treatment
-----------------
* Procedure: Laparoscopic cystectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: no ovarian surgery before Exclusion Criteria: Endocrinological pathologies Suspicion of malignancy in preoperative laboratory and ultrasonographic evaluations Detection of malignancy in histopathological examination

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Endometrioma<br>Participants who will have endometrioma after histopathological evaluation. | Procedure: Laparoscopic cystectomy<br>* All surgeries will be performed under general anesthesia by laparoscopically.<br>|
| Active Comparator: Mature cystic teratoma (dermoid cyst)<br>Participants who will have mature cystic teratoma (dermoid cyst) after histopathological evaluation. | Procedure: Laparoscopic cystectomy<br>* All surgeries will be performed under general anesthesia by laparoscopically.<br>|
| Active Comparator: Serous or mucinous cystadenoma<br>Participants who will have serous or mucinous cystadenoma after histopathological evaluation. | Procedure: Laparoscopic cystectomy<br>* All surgeries will be performed under general anesthesia by laparoscopically.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in AMH Level | AMH levels of the participants will be investigated before the surgery and 6 months after the surgery. | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ovarian reserve, anti-mullerian hormone, ovarian cyst